Scale drug discovery with quantum-inspired physics and generative AI AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data. We are … [voir plus]

Transforming how molecular biology translates to human health, personalized medicine and synthetic biology DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAXTM️, the world’s … [voir plus]

Delivering the promise of immunotherapy Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological … [voir plus]

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic ImCheck Therapeutics an @Ipsen company designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. [voir plus]

Innovative personalized therapies targeting TREM-1 for life-threatening inflammatory syndromes such as septic shock Inotrem is a French biopharmaceutical company founded in 2013, with offices in Paris and a technology center in Nancy (France). Our mission is to improve public health by developing a new class of therapeutic solutions targeting the … [voir plus]

Empower the body, cure the disease Mnemo Therapeutics is a Paris-based biotechnology company driven to create powerful immunotherapies by improving the body’s ability to detect and eradicate cancer. The paucity of actionable cancer-specific targets creates significant challenges in the field of immuno-oncology. To address this, Mnemo has developed a combination … [voir plus]

Formerly Umiami | The tender, juicy whole filet made from plants. We make delicious, clean-label meat replacements from plants. Our first product, SWAP Filet (SWAP Chicken in the United States) is a thick, whole filet that closely replicates the taste, texture and appearance of chicken using a short list of … [voir plus]

Biomorphic Programmable Polymers TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, … [voir plus]

Cell Therapy for All TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant … [voir plus]

Ordinary life for Extraordinary people Revolutionizing mobility with self-balancing robotics We're hiring worldwide! https://wandercraft.welcomekit.co/ At Wandercraft, we believe movement is freedom. Since 2012, our mission has been simple but bold: restore mobility where it’s been lost, and expand what’s possible with robotics that move like people do. We see robotics … [voir plus]

Dynacure is a clinical-stage company focused on developing novel therapies for rare diseases. Dynacure is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Dynacure is developing DYN101, an investigational antisense product candidate … [voir plus]

Développer des thérapies pour les maladies rénales chroniques ENYO Pharma développe des traitements thérapeutiques innovants basés sur des propriétés fibrolytiques et anti-inflammatoires pour les maladies associées à une insuffisance rénale. La société mène actuellement des essais de phase 2 avec son composé phare, le Vonafexor, dans le traitement des maladies … [voir plus]

We create ophthalmic therapeutic bio factories to sustainably treat major eye diseases. Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. EyeCET stands for the eye ciliary muscle electro-transfection … [voir plus]